Swathi Iyer

Employment

• Sloan-Kettering Institute Research Scholar
  2017 - Present

Education

• University of Kansas Medical Center Ph.D.
  2011 - 2016

Projects & Funding

Projects & funding information is unavailable.

Publications (13)

• Gliocidin is a nicotinamide-mimetic prodrug that targets glioblastoma
  Nature 2024 DOI: 10.1038/s41586-024-08224-z
  +Save
• MTBP inhibits the Erk1/2-Elk-1 signaling in hepatocellular carcinoma
  Oncotarget 2018 DOI: 10.18632/oncotarget.25117
  +Save
• Novel siRNA formulation to effectively knockdown mutant p53 in osteosarcoma
  PLOS ONE 2017 DOI: 10.1371/journal.pone.0179168
  +Save
• Suppressive roles of A3AR and TMIGD3 i1 in osteosarcoma malignancy
  Cell Cycle 2017 DOI: 10.1080/15384101.2017.1308153
  +Save
• Abstract B24: Regulation of mutant p53 stability by the mevalonate pathway-Hsp40-CHIP axis
  Oncoproteins for Degradation 2017 DOI: 10.1158/1557-3265.pmccavuln16-b24
  +Save
• Genome-wide RNAi screening identifies TMIGD3 isoform1 as a suppressor of NF-κB and osteosarcoma progression
  Nature Communications 2016 DOI: 10.1038/ncomms13561
  +Save
• DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway
  Nature Cell Biology 2016 DOI: 10.1038/ncb3427
  +Save
• Abstract 3690: Metabolic regulation of mutant p53 stability by the mevalonate pathway
  Cancer Research 2016 DOI: 10.1158/1538-7445.am2016-3690
  +Save
• An improved intrafemoral injection with minimized leakage as an orthotopic mouse model of osteosarcoma
  Analytical Biochemistry 2015 DOI: 10.1016/j.ab.2015.06.030
  +Save
• Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities
  Oncotarget 2015 DOI: 10.18632/oncotarget.6634
  +Save